Ocular Changes Induced in the Beagle Dog by Intravenous Infusion of a Novel Dopaminergic Compound,FPL 65447

Abstract

FPL 65447, a selective D₁ receptor agonist with a potential for the acute treatment of renal and cardiac failure and of sepsis and septic shock, was administered to beagle dogs by continuous intravenous infusion for a maximum of 14 days. Ophthalmoscopical examination revealed dose-related changes in the eye and associated structures, consisting of foci of retinal discolouration, corneal changes including oedema, keratitis, opacities and neovascularisation, and inflammation of the iris, periorbital tissues, and adnexa. Microscopical examination confirmed the presence of inflammatory lesions in the eye. These were predominantly histiocytic and were mainly focal circumscribed lesions. More diffuse inflammation with a granulocytic and lymphocytic component was also encountered in the limbus and uveal tract. A predominantly interstitial histiocytic adenitis involving various glandular structures associated with the eye and adnexa was also identified. Possible mechanisms to account for the histiocytic changes are discussed.

Keywords

D1 agonist ocular inflammation focal histiocytic changes adenitis

References

1. Duffy PA , Westwood FR , Malpass DA , Topham J , and Jones GY (1992). Induction of histiocyte aggregates by the thromboxane antagonist ICI 185.282 in dogs: An investigation of potential mechanisms. Toxicol. Lett. (Suppl) 289.

2. Fawcett DW (1986). Bloom and Fawcett: ATextbook of Histology, 11th ed. W. B. Saunders, Philadelphia, pp. 913–960.

3. Heywood R (1982). Histopathological and laboratory assessment of visual dysfunction. Environ. Health Perspect 44: 35–45.

4. Kerns WD , Arena E , Maria RA , Bugelski PJ , Matthews WD , and Morgan DG (1989). Pathogenesis of arterial lesions induced by dopaminergic compounds in the rat. Toxicol. Pathol 17: 203–213.

5. Lee WR (1992). The eye. In: Muir's Textbook of Pathology, RNM MacSween and K Whaley (eds). Edward Arnold, London, pp. 880–890.

6. Moore PF (1984). Systemic histiocytosis of Bernese mountain dogs. Vet. Pathol 21: 554–563

7. Moore PF (1986). Utilization of cytoplasmic lysozyme immunoreactivity as a histiocytic marker in canine histiocytic disorders. Vet. Pathol 23: 757–762.

8. Moore PF and Rosin A (1986). Malignant histiocytosis of Bernese mountain dogs. Vet. Pathol 23: 1–10.

9. Schiavo DM , Sinha DP , Black HE , Arthaud L , Massa T , Murphy BF , Szot RJ , and Schwartz E (1984). Tapetal changes in beagle dogs: Ocular changes after oral administration of a beta-adrenergic blocking agent—SCH 19927. Toxicol. Appl. Pharmacol 72: 187–194.

10.

10. Smith GW, Christie MI, Ince F, Nicol AK, Springthorpe B, Williams GE, and Verity A (in press). FPL 65447AA: A selective DA,-receptor agonist. Clin. Exp. Hypertension (abstract).

11.

11. Tanaka N , Ohkawa T , Hiyama T , and Nakajima A (1983). Evaluation of ocular toxicity of two beta blocking drugs, carteolol and practolol, in beagle dogs. J. Pharmacol. Exp. Ther 224: 424–430.